Bispecific human IgG by design

Journal of Immunological Methods

Volumn 248, Issue 1-2, 2001, Pages 7-15

  Carter, Paul ^a,b  

^a GENENTECH INC   (United States)

^b AMGEN INC   (United States)

Author keywords

Antibody engineering; Bispecific antibodies; Immunotherapy

Indexed keywords

BISPECIFIC ANTIBODY; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN;

ANTIBODY PRODUCTION; ANTIGEN BINDING; ANTIGEN SPECIFICITY; BINDING AFFINITY; DIMERIZATION; ESCHERICHIA COLI; GENETIC ENGINEERING; IMMUNOGENICITY; IMMUNOTHERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REVIEW;

ANTIBODIES, BISPECIFIC; DIMERIZATION; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN HEAVY CHAINS; PROTEIN ENGINEERING;

ESCHERICHIA COLI;

EID: 0035251453     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-1759(00)00339-2     Document Type: Review

References (50)

1. Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library
2. HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer
3. 1 fragments
4. Bispecific antibodies as novel bioconjugates
5. A phase 1B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: Specific targeting without immunogenicity
6. High level Escherichia coli expression and production of a bivalent humanized antibody fragment
7. HER2 antibody for human cancer therapy
8. Toward the production of bispecific antibody fragments for clinical applications
9. A humanized, bispecific immunoadhesin-antibody that retargets CD3+ effectors to kill HIV-1-infected cells
10. Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8-Å resolution
11. Bispecific receptor globulins, novel tools for the study of cellular interactions. Preparation and characterization of an E-selectin/P-selectin bispecific receptor globulin
12. In vitro assembly of repertoires of antibody chains on the surface of phage by renaturation
13. 2 antibody containing thioether-linked Fab′γ fragments
14. Recent results using CAMPATH-1 antibodies to control GVHD and graft rejection
15. Ribosome display efficiently selects and evolves high-affinity antibodies in vitro from immune libraries
16. 'Diabodies': Small bivalent and bispecific antibody fragments
17. Retargeting serum immunoglobulin with bispecific diabodies
18. High volumetric yields of functional dimeric miniantibodies in Escherichia coli, using an optimized expression vector and high-cell-density fermentation under non-limited growth conditions
19. Recombinant antibody constructs in cancer therapy
20. Humanised monoclonal antibody therapy for rheumatoid arthritis
21. Expression, purification and characterization of a mouse-human chimeric antibody and chimeric Fab′ fragment
22. Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides
23. Bispecific antibodies in cancer therapy, from the laboratory to the clinic
24. Complement recruitment using bispecific diabodies
25. HER2 monoclonal antibodies
26. An efficient route to human bispecific IgG
27. Protein-protein recognition and the association of immunoglobulin constant domains
28. Hybrid hybridomas and their use in immunohistochemistry
29. A dimeric bispecific miniantibody combines two specificities with avidity
30. Antibody fragments from a 'single pot' phage display library as immunochemical reagents
31. Improved bivalent miniantibodies, with identical avidity as whole antibodies, produced by high cell density fermentation of Escherichia coli
32. Tetravalent miniantibodies with high avidity assembling in Escherichia coli
33. Miniantibodies: Use of amphipathic helices to produce functional, flexibly linked dimeric Fv fragments with high avidity in Escherichia coli
34. New protein engineering approaches to multivalent and bispecific antibody fragments
35. The rise of monoclonal antibodies as therapeutics
36. H3 domains for heavy chain heterodimerization
37. 2 fragment for improved binding to T cells
38. Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site
39. Bispecific antibodies in cancer therapy
40. Development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overexpressing the HER2 protooncogene
41. Evaluation of a complementarity-determining region-grafted (humanized) anti-carcinoembryonic antigen monoclonal antibody in preclinical and clinical studies
42. Bispecific monoclonal antibodies from hybrid hybridomas
43. Advantages of bispecific hybridomas in one-step immunocytochemistry and immunoassays
44. Human antibodies by design
45. Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library
46. A phase I trial of humanized anti-interleukin 2 receptor antibody in renal transplantation
47. CDR walking mutagenesis for the affinity maturation of a potent human anti-HIV-1 antibody into the picomolar range
48. Remodeling domain interfaces to enhance heterodimer formation
49. High level secretion of a humanized bispecific diabody from Escherichia coli